Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from ZyVersa Therapeutics ( (ZVSA) ) is now available.
ZyVersa Therapeutics, Inc. held its 2025 annual meeting of stockholders on June 11, 2025, where several key proposals were voted upon. Stockholders approved the amendment and restatement of the 2022 Omnibus Equity Incentive Plan, increasing the shares reserved for issuance by 100,000 to a total of 382,122 shares. Additionally, the election of Class III directors, ratification of auditors, and approval of the issuance of shares upon exercise of certain warrants were also passed, indicating strong shareholder support for the company’s strategic initiatives.
The most recent analyst rating on (ZVSA) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on ZyVersa Therapeutics stock, see the ZVSA Stock Forecast page.
Spark’s Take on ZVSA Stock
According to Spark, TipRanks’ AI Analyst, ZVSA is a Underperform.
ZyVersa Therapeutics faces significant financial challenges with no revenue and ongoing losses. Technical indicators show bearish momentum, and the negative P/E ratio suggests overvaluation concerns. The lack of dividend yield further limits investment appeal.
To see Spark’s full report on ZVSA stock, click here.
More about ZyVersa Therapeutics
Average Trading Volume: 3,662,317
Technical Sentiment Signal: Sell
Current Market Cap: $3.34M
For detailed information about ZVSA stock, go to TipRanks’ Stock Analysis page.